Teva pharmaceuncais knows the business of drug patents from both sides now. It grew to immense sales making knockoffs of other companies' drugs as they went off patent Now, looking for better returns, it is investing heavily in drug research and getting its own patents-only to suffer when yet other companies knock them off Says Credit Suisse analyst Marc Goodman: "Now Teva understands what it's like to be Big Pharma. They're getting a taste of their own medicine." With or without the dramatic irony, producing drugs is a lucrative business. Teva, which is based in Jerusalem, hauled in $9.4 billion of revenue last year. Its 21% net profit margin is ahead of Pfizer's and Eli Lilly's. If Teva's earnings per share this year meet the Wall Street expectation of $2.72, they will have climbed tenfold in. eight years.
展开▼
